<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 30.5 - Myelofibrosis</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 30.5 - Myelofibrosis | MD3 SCP Cases">
  <meta name="description" content="A 68-year-old with post-ET myelofibrosis presenting with massive splenomegaly, constitutional symptoms, tear-drop cells, and leukoerythroblastic blood film. Learn about MPNs, JAK2 mutations, DIPSS scoring, ruxolitinib, and allogeneic HSCT.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:title" content="Case 30.5 - Myelofibrosis">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="A 68-year-old with post-ET myelofibrosis presenting with massive splenomegaly, constitutional symptoms, tear-drop cells, and leukoerythroblastic blood film. Learn about MPNs, JAK2 mutations, DIPSS scoring, ruxolitinib, and allogeneic HSCT.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 30.5 – Myelofibrosis</h1>
    <p class="meta"><strong>Category:</strong> Medicine | <strong>Discipline:</strong> Haematology | <strong>Setting:</strong> Haematology Clinic</p>

    <h2>Case</h2>
    <p>Mrs. Eileen Watson, a 68-year-old retired librarian, is referred to the haematology clinic by her GP with a 6-month history of progressive fatigue, weight loss (7kg), early satiety, and left upper quadrant discomfort. She reports drenching night sweats and bone pain, particularly affecting her ribs and sternum. Over the past month, she has noticed a dragging sensation in her left abdomen.</p>

    <p>Her past medical history includes hypertension managed with amlodipine. She has never smoked and drinks alcohol occasionally. On direct questioning, she denies any history of bleeding or thrombosis, but mentions she had essential thrombocythaemia diagnosed 8 years ago, which was initially managed with aspirin and later hydroxycarbamide due to rising platelet counts.</p>

    <div class="vital-signs">
      <strong>On Examination:</strong>
      <ul>
        <li>General: Pale, appears chronically unwell, cachectic</li>
        <li>Temperature: 37.8°C, Heart rate: 98 bpm, BP: 138/82 mmHg, RR: 18/min, SpO₂: 96% on air</li>
        <li>Cardiovascular: Tachycardic, no murmurs, no signs of heart failure</li>
        <li>Respiratory: Clear chest</li>
        <li>Abdomen: <strong>Massive splenomegaly</strong> - spleen palpable 12cm below left costal margin extending across midline. Moderate hepatomegaly (liver 4cm below right costal margin). No ascites. Mild tenderness over sternum.</li>
        <li>Lymph nodes: No palpable lymphadenopathy</li>
        <li>Skin: Pale, no petechiae or purpura</li>
      </ul>
    </div>

    <h2>Investigations</h2>
    <div class="investigation-results">
      <strong>Full Blood Count:</strong>
      <ul>
        <li>Hb: 82 g/L (normal 115-165 g/L for women) - Anaemia</li>
        <li>WCC: 18.5 × 10⁹/L (normal 4-11 × 10⁹/L) - Leucocytosis</li>
        <li>Neutrophils: 12.8 × 10⁹/L</li>
        <li>Platelets: 650 × 10⁹/L (normal 150-400 × 10⁹/L) - Thrombocytosis</li>
        <li>MCV: 98 fL (normal 80-100 fL)</li>
        <li>Reticulocytes: 3.2% (elevated)</li>
      </ul>
      <strong>Blood Film:</strong>
      <ul>
        <li><strong>Leukoerythroblastic picture:</strong> Nucleated red blood cells (nRBCs) and immature white cells (myelocytes, metamyelocytes) in peripheral blood</li>
        <li><strong>Tear-drop cells (dacrocytes)</strong> - characteristic finding</li>
        <li>Anisocytosis, poikilocytosis</li>
        <li>Giant platelets</li>
      </ul>
      <br>
      <strong>Biochemistry:</strong>
      <ul>
        <li>LDH: 850 U/L (normal 100-250 U/L) - elevated</li>
        <li>Uric acid: 520 μmol/L (normal 200-430 μmol/L) - elevated</li>
        <li>Bilirubin: 28 μmol/L (mildly elevated, unconjugated)</li>
        <li>ALT: 42 U/L, ALP: 180 U/L</li>
        <li>Creatinine: 95 μmol/L (normal)</li>
      </ul>
      <strong>JAK2 Mutation:</strong> <strong>Positive (JAK2 V617F mutation detected)</strong>
      <br><br>
      <strong>Bone Marrow Biopsy:</strong>
      <ul>
        <li><strong>Hypercellular marrow with trilineage hyperplasia</strong></li>
        <li><strong>Grade 3 reticulin fibrosis (severe)</strong> on reticulin stain</li>
        <li>Increased megakaryocytes with abnormal morphology (clustering, cloud-like nuclei)</li>
        <li>Difficult to aspirate ("dry tap") - minimal material obtained</li>
      </ul>
    </div>

    <h2>Questions</h2>

    <div class="question">
      <h3>Question 1: What is the most likely diagnosis, and how is this condition classified within the broader spectrum of myeloproliferative neoplasms?</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Diagnosis: Primary Myelofibrosis (PMF)</strong></p>

        <p>This patient has transitioned from essential thrombocythaemia (ET) to <strong>post-ET myelofibrosis</strong>, which is now classified as Primary Myelofibrosis (PMF) in its fibrotic stage.</p>

        <p><strong>Classification - Myeloproliferative Neoplasms (MPNs):</strong></p>
        <p>MPNs are clonal haematopoietic stem cell disorders characterized by proliferation of one or more myeloid cell lines. The Philadelphia chromosome-negative MPNs include:</p>

        <table>
          <tr>
            <th>Condition</th>
            <th>Main Cell Line Affected</th>
            <th>Key Features</th>
          </tr>
          <tr>
            <td><strong>Polycythaemia Vera (PV)</strong></td>
            <td>Red blood cells (↑ Hb)</td>
            <td>
              ↑ Hb/Hct, ↑ RBC mass, splenomegaly, pruritus (especially after hot bath), erythromelalgia, thrombosis risk.
              JAK2 V617F +ve in 95%
            </td>
          </tr>
          <tr>
            <td><strong>Essential Thrombocythaemia (ET)</strong></td>
            <td>Platelets (↑ PLT)</td>
            <td>
              Sustained thrombocytosis (\&gt;450 × 10⁹/L), thrombosis or bleeding, splenomegaly (mild).
              JAK2 V617F +ve in 50-60%, CALR +ve in 20-25%, MPL +ve in 3-5%
            </td>
          </tr>
          <tr>
            <td><strong>Primary Myelofibrosis (PMF)</strong></td>
            <td>All lines (variable blood counts)</td>
            <td>
              <strong>Massive splenomegaly</strong>, bone marrow fibrosis, leukoerythroblastic blood film, tear-drop cells, constitutional symptoms.
              JAK2 V617F +ve in 50-60%, CALR +ve in 25%, MPL +ve in 8%
            </td>
          </tr>
        </table>

        <p><strong>Disease Progression - Spent Phase:</strong></p>
        <p>Both PV and ET can progress to <strong>myelofibrosis</strong> (post-PV MF or post-ET MF) in 10-20% of cases over 10-15 years. This represents the "spent phase" of the disease, where:</p>
        <ul>
          <li>The bone marrow becomes progressively fibrotic</li>
          <li>Extramedullary haematopoiesis develops (spleen, liver)</li>
          <li>Blood counts change from proliferative phase (high counts) to cytopenias</li>
          <li>Massive splenomegaly develops</li>
          <li>Constitutional symptoms worsen</li>
          <li>Prognosis worsens significantly</li>
        </ul>

        <p><strong>Evidence for Post-ET Myelofibrosis in This Case:</strong></p>
        <ul>
          <li>History of essential thrombocythaemia diagnosed 8 years ago</li>
          <li>Now presenting with massive splenomegaly (12cm - hallmark of myelofibrosis)</li>
          <li>Bone marrow fibrosis (grade 3 - severe)</li>
          <li>Leukoerythroblastic blood film with tear-drop cells (pathognomonic)</li>
          <li>Constitutional symptoms (fatigue, weight loss, night sweats, bone pain)</li>
          <li>JAK2 V617F positive (consistent with MPN)</li>
          <li>"Dry tap" on bone marrow aspiration (due to fibrosis)</li>
        </ul>

        <p><strong>WHO Diagnostic Criteria for Primary Myelofibrosis:</strong></p>
        <p>Requires all 3 <strong>major criteria</strong> PLUS at least 1 <strong>minor criterion</strong>:</p>

        <p><strong>Major Criteria:</strong></p>
        <ol>
          <li><strong>Megakaryocytic proliferation and atypia</strong> with either reticulin and/or collagen fibrosis (grade 2-3)</li>
          <li><strong>Not meeting WHO criteria for other MPNs</strong> (PV, ET, CML, MDS, or other myeloid neoplasm)</li>
          <li><strong>Presence of JAK2, CALR, or MPL mutation</strong>, OR in absence of these mutations, presence of another clonal marker or no evidence of reactive marrow fibrosis</li>
        </ol>

        <p><strong>Minor Criteria:</strong></p>
        <ul>
          <li>Anaemia not attributed to other causes</li>
          <li>Leucocytosis ≥11 × 10⁹/L</li>
          <li>Palpable splenomegaly</li>
          <li>Elevated LDH</li>
          <li><strong>Leukoerythroblastic blood picture</strong></li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>Question 2: Explain the pathophysiology of myelofibrosis and discuss why this patient has massive splenomegaly, constitutional symptoms, and a leukoerythroblastic blood film with tear-drop cells.</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Pathophysiology of Myelofibrosis:</strong></p>

        <p><strong>1. Initiating Event - Clonal Stem Cell Mutation:</strong></p>
        <ul>
          <li>Acquired somatic mutations in haematopoietic stem cells:
            <ul>
              <li><strong>JAK2 V617F</strong> (50-60% of cases) - gain-of-function mutation in JAK-STAT signaling pathway</li>
              <li><strong>CALR</strong> (calreticulin, 25% of cases) - affects calcium signaling and JAK-STAT pathway</li>
              <li><strong>MPL</strong> (thrombopoietin receptor, 8% of cases)</li>
              <li>Triple-negative (10-15%) - other mutations may be present</li>
            </ul>
          </li>
          <li>These mutations lead to <strong>constitutive activation of JAK-STAT signaling</strong> → cytokine-independent proliferation of myeloid cells</li>
        </ul>

        <p><strong>2. Abnormal Megakaryocyte Proliferation and Cytokine Release:</strong></p>
        <ul>
          <li>Clonal proliferation of <strong>abnormal megakaryocytes</strong> in bone marrow</li>
          <li>These megakaryocytes release excessive pro-fibrotic cytokines:
            <ul>
              <li><strong>TGF-β (transforming growth factor-beta)</strong> - most important pro-fibrotic cytokine</li>
              <li>PDGF (platelet-derived growth factor)</li>
              <li>VEGF (vascular endothelial growth factor)</li>
              <li>FGF (fibroblast growth factor)</li>
            </ul>
          </li>
        </ul>

        <p><strong>3. Reactive Bone Marrow Fibrosis:</strong></p>
        <ul>
          <li>Cytokines stimulate <strong>reactive proliferation of fibroblasts</strong> (NOT part of malignant clone)</li>
          <li>Fibroblasts deposit excessive <strong>reticulin and collagen</strong> in marrow stroma</li>
          <li>Progressive replacement of normal marrow architecture with fibrotic tissue</li>
          <li>Bone marrow becomes hypocellular and fibrotic → "dry tap" on aspiration</li>
        </ul>

        <p><strong>4. Extramedullary Haematopoiesis (EMH):</strong></p>
        <ul>
          <li>As bone marrow fails, haematopoietic stem cells migrate to fetal sites of blood production:</li>
          <li><strong>Spleen</strong> (main site) → massive splenomegaly</li>
          <li><strong>Liver</strong> → hepatomegaly</li>
          <li>Other sites: Lymph nodes, lungs, kidneys, adrenal glands, skin, GI tract, pleura, spine (can cause cord compression)</li>
        </ul>

        <p><strong>5. Release of Immature Cells into Circulation:</strong></p>
        <ul>
          <li>EMH sites release immature cells into bloodstream → <strong>leukoerythroblastic picture</strong></li>
        </ul>

        <p><strong>Clinical Manifestations - Explained:</strong></p>

        <table>
          <tr>
            <th>Feature</th>
            <th>Pathophysiological Mechanism</th>
          </tr>
          <tr>
            <td><strong>Massive Splenomegaly<br>(12cm below costal margin)</strong></td>
            <td>
              <strong>Extramedullary haematopoiesis</strong> - spleen becomes main site of blood cell production as marrow fails.
              Progressive splenic enlargement can lead to:
              <ul>
                <li>Early satiety (stomach compression)</li>
                <li>Left upper quadrant pain/discomfort</li>
                <li>Dragging sensation</li>
                <li>Splenic infarction (severe pain)</li>
                <li>Portal hypertension (in severe cases)</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Constitutional Symptoms<br>(fatigue, weight loss, night sweats, fever)</strong></td>
            <td>
              <strong>Hypercatabolic state</strong> from:
              <ul>
                <li>Increased cell turnover (high LDH reflects this)</li>
                <li>Inflammatory cytokine release (IL-1, IL-6, TNF-α)</li>
                <li>Massive spleen consuming energy</li>
                <li>Ineffective haematopoiesis</li>
              </ul>
              These symptoms significantly impair quality of life
            </td>
          </tr>
          <tr>
            <td><strong>Bone Pain<br>(ribs, sternum, long bones)</strong></td>
            <td>
              <ul>
                <li><strong>Bone marrow expansion</strong> and stretching of periosteum</li>
                <li><strong>Increased osteosclerosis</strong> (new bone formation in response to fibrosis)</li>
                <li>Visible on imaging as increased bone density, particularly in axial skeleton</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Leukoerythroblastic Blood Film</strong></td>
            <td>
              Presence of:
              <ul>
                <li><strong>Nucleated RBCs (nRBCs)</strong> in peripheral blood</li>
                <li><strong>Immature white cells</strong> (myelocytes, metamyelocytes, blasts)</li>
              </ul>
              Caused by:
              <ul>
                <li>Extramedullary haematopoiesis releasing immature cells</li>
                <li>Disrupted marrow architecture allowing premature release</li>
              </ul>
              <strong>Differential diagnosis of leukoerythroblastic picture:</strong>
              <ul>
                <li>Myelofibrosis (primary or secondary)</li>
                <li>Marrow infiltration (metastatic cancer, lymphoma, leukaemia)</li>
                <li>Severe haemolysis or bleeding (marrow stress)</li>
                <li>Severe infection/sepsis</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Tear-Drop Cells<br>(Dacrocytes)</strong></td>
            <td>
              <strong>Pathognomonic for myelofibrosis</strong> (though not 100% specific)
              <br><br>
              Mechanism:
              <ul>
                <li>RBCs physically deformed as they squeeze through <strong>fibrotic marrow sinusoids</strong></li>
                <li>RBCs also deformed passing through congested splenic cords (splenic pooling/congestion)</li>
                <li>Result: Teardrop or pear-shaped RBCs</li>
              </ul>
              Presence strongly suggests marrow fibrosis or marrow infiltration
            </td>
          </tr>
          <tr>
            <td><strong>Anaemia</strong></td>
            <td>
              Multifactorial:
              <ul>
                <li>Ineffective erythropoiesis (fibrotic marrow)</li>
                <li>Splenic sequestration (hypersplenism)</li>
                <li>Shortened RBC survival</li>
                <li>Haemodilution (expanded plasma volume from massive spleen)</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Leucocytosis + Thrombocytosis<br>(early) or Cytopenias (late)</strong></td>
            <td>
              <strong>Early/proliferative phase:</strong> Clonal myeloproliferation → high counts
              <br><br>
              <strong>Late/fibrotic phase:</strong> Marrow failure + hypersplenism → cytopenias
              <br><br>
              This patient has mixed picture (leucocytosis + thrombocytosis BUT anaemia) - typical of intermediate stage
            </td>
          </tr>
        </table>

        <p><strong>Laboratory Markers of Disease Activity:</strong></p>
        <ul>
          <li><strong>↑ LDH:</strong> Reflects increased cell turnover and ineffective haematopoiesis</li>
          <li><strong>↑ Uric acid:</strong> High cell turnover → purine metabolism → hyperuricaemia (gout risk)</li>
          <li><strong>↑ Unconjugated bilirubin:</strong> Ineffective erythropoiesis and haemolysis</li>
        </ul>

        <p><strong>"Dry Tap" on Bone Marrow Aspiration:</strong></p>
        <ul>
          <li>Dense reticulin/collagen fibrosis prevents aspiration of marrow contents</li>
          <li>Trephine biopsy essential for diagnosis (provides core of tissue for histology and reticulin staining)</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <h3>Question 3: How would you assess disease severity and prognosis in this patient, and what are the management options for myelofibrosis, including the role of JAK inhibitors and haematopoietic stem cell transplantation?</h3>
      <button class="toggle-answer">Show Answer</button>
      <div class="answer">
        <p><strong>Prognostic Scoring Systems:</strong></p>

        <p><strong>DIPSS (Dynamic International Prognostic Scoring System):</strong></p>
        <p>Most commonly used system for risk stratification. Assigns points for adverse features (can be calculated at any time, not just diagnosis):</p>

        <table>
          <tr>
            <th>Risk Factor</th>
            <th>Points</th>
          </tr>
          <tr>
            <td>Age >65 years</td>
            <td>1</td>
          </tr>
          <tr>
            <td>Constitutional symptoms (weight loss, night sweats, fever)</td>
            <td>1</td>
          </tr>
          <tr>
            <td>Haemoglobin &lt;100 g/L</td>
            <td>2</td>
          </tr>
          <tr>
            <td>Leucocyte count >25 × 10⁹/L</td>
            <td>1</td>
          </tr>
          <tr>
            <td>Circulating blasts ≥1%</td>
            <td>1</td>
          </tr>
        </table>

        <p><strong>Risk Categories:</strong></p>
        <ul>
          <li><strong>Low risk (0 points):</strong> Median survival >15 years</li>
          <li><strong>Intermediate-1 (1-2 points):</strong> Median survival ~6 years</li>
          <li><strong>Intermediate-2 (3-4 points):</strong> Median survival ~3 years</li>
          <li><strong>High risk (≥5 points):</strong> Median survival ~1.5 years</li>
        </ul>

        <p><strong>This Patient's DIPSS Score:</strong></p>
        <ul>
          <li>Age 68 years: <strong>+1</strong></li>
          <li>Constitutional symptoms (fatigue, weight loss, night sweats, bone pain): <strong>+1</strong></li>
          <li>Hb 82 g/L (\&lt;100): <strong>+2</strong></li>
          <li>WCC 18.5 × 10⁹/L (\&lt;25): 0</li>
          <li>No mention of circulating blasts ≥1%: 0</li>
          <li><strong>Total: 4 points = Intermediate-2 risk (median survival ~3 years)</strong></li>
        </ul>

        <p><strong>Additional Poor Prognostic Factors:</strong></p>
        <ul>
          <li>Previous MPN (post-ET myelofibrosis) - slightly worse prognosis than de novo PMF</li>
          <li>Transfusion dependence</li>
          <li>Thrombocytopenia (\&lt;100 × 10⁹/L)</li>
          <li>Unfavorable karyotype</li>
          <li>Absence of CALR mutation (worse prognosis if triple-negative or JAK2+)</li>
          <li>High-molecular-risk mutations (ASXL1, EZH2, SRSF2, IDH1/2)</li>
        </ul>

        <p><strong>Complications to Monitor:</strong></p>
        <ul>
          <li><strong>Transformation to acute myeloid leukaemia (AML):</strong> 10-20% risk, poor prognosis</li>
          <li><strong>Thrombosis:</strong> Arterial or venous (paradoxically despite thrombocytosis)</li>
          <li><strong>Bleeding:</strong> From thrombocytopenia or dysfunctional platelets or portal hypertension</li>
          <li><strong>Portal hypertension:</strong> From massive splenomegaly and hepatomegaly</li>
          <li><strong>Splenic infarction:</strong> Severe left upper quadrant pain</li>
          <li><strong>Gout/hyperuricaemia:</strong> From high cell turnover</li>
          <li><strong>Extramedullary haematopoiesis complications:</strong> Cord compression, pleural/pericardial effusions</li>
        </ul>

        <p><strong>Management of Myelofibrosis:</strong></p>

        <p><strong>1. Risk-Adapted Approach:</strong></p>

        <table>
          <tr>
            <th>Risk Category</th>
            <th>Management Strategy</th>
          </tr>
          <tr>
            <td><strong>Low Risk<br>(Asymptomatic)</strong></td>
            <td>
              <strong>Watch and wait</strong>
              <ul>
                <li>Regular monitoring (FBC every 3-6 months)</li>
                <li>Patient education</li>
                <li>Address if symptoms develop</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Intermediate-1 Risk<br>(Mild symptoms)</strong></td>
            <td>
              <strong>Symptomatic management + consider JAK inhibitors</strong>
              <ul>
                <li>Treat anaemia (transfusions, EPO, androgens)</li>
                <li>Manage splenomegaly if symptomatic</li>
                <li>JAK inhibitor if constitutional symptoms</li>
              </ul>
            </td>
          </tr>
          <tr>
            <td><strong>Intermediate-2 / High Risk<br>(Symptomatic, poor prognosis)</strong></td>
            <td>
              <strong>JAK inhibitors + consider allogeneic HSCT</strong>
              <ul>
                <li>JAK inhibitor (ruxolitinib) for spleen/symptoms</li>
                <li><strong>Allogeneic HSCT if eligible</strong> (ONLY curative option)</li>
                <li>Clinical trial enrollment</li>
              </ul>
            </td>
          </tr>
        </table>

        <p><strong>2. Specific Treatment Options:</strong></p>

        <p><strong>A. JAK Inhibitors - Ruxolitinib (First-line):</strong></p>
        <ul>
          <li><strong>Mechanism:</strong> Selective JAK1/JAK2 inhibitor → blocks JAK-STAT signaling pathway</li>
          <li><strong>Indications:</strong>
            <ul>
              <li>Splenomegaly (reduces spleen size in 70-80%)</li>
              <li>Constitutional symptoms (improves in 50-70%)</li>
              <li>Intermediate-2 or high-risk disease</li>
            </ul>
          </li>
          <li><strong>Benefits:</strong>
            <ul>
              <li>Rapid reduction in spleen size (median 30-40% volume reduction)</li>
              <li>Improvement in symptoms (fatigue, night sweats, bone pain, pruritus)</li>
              <li>Improved quality of life</li>
              <li>Possible survival benefit (especially in high-risk patients)</li>
            </ul>
          </li>
          <li><strong>Limitations:</strong>
            <ul>
              <li><strong>NOT curative</strong> - does not reduce marrow fibrosis or eliminate malignant clone</li>
              <li>Does NOT prevent progression to AML</li>
              <li>Side effects: <strong>Anaemia (dose-limiting), thrombocytopenia, infections, diarrhoea</strong></li>
              <li>Withdrawal syndrome (abrupt stopping → rebound symptoms, cytokine storm)</li>
            </ul>
          </li>
          <li><strong>Dosing:</strong> Starting dose 15-20mg BD, adjust based on blood counts</li>
        </ul>

        <p><strong>B. Allogeneic Haematopoietic Stem Cell Transplantation (HSCT):</strong></p>
        <ul>
          <li><strong>ONLY curative treatment for myelofibrosis</strong></li>
          <li><strong>Indications:</strong>
            <ul>
              <li>Intermediate-2 or high-risk disease (DIPSS ≥3)</li>
              <li>Age &lt;70 years (biological age, not chronological)</li>
              <li>Adequate organ function</li>
              <li>Available donor (matched sibling or matched unrelated)</li>
            </ul>
          </li>
          <li><strong>Outcomes:</strong>
            <ul>
              <li>5-year overall survival: 50-60%</li>
              <li>Better outcomes if: Younger age, lower risk disease, matched sibling donor, pre-transplant JAK inhibitor (reduces spleen size)</li>
            </ul>
          </li>
          <li><strong>Risks:</strong>
            <ul>
              <li><strong>Treatment-related mortality (TRM): 10-20%</strong> (higher than other haematological malignancies due to splenomegaly, older age, comorbidities)</li>
              <li>Graft failure (5-10% - higher in MF due to fibrotic marrow)</li>
              <li>Graft-versus-host disease (GVHD)</li>
              <li>Infections</li>
            </ul>
          </li>
          <li><strong>Pre-transplant strategies:</strong>
            <ul>
              <li>Ruxolitinib for 3-6 months (reduce spleen, improve performance status, taper before transplant to avoid withdrawal)</li>
              <li>Splenectomy if massive splenomegaly (controversial - increases surgical mortality)</li>
              <li>Reduced-intensity conditioning (RIC) preferred in older patients</li>
            </ul>
          </li>
        </ul>

        <p><strong>C. Management of Anaemia:</strong></p>
        <ul>
          <li><strong>Red blood cell transfusions:</strong> For symptomatic anaemia (aim Hb >80 g/L)</li>
          <li><strong>Erythropoiesis-stimulating agents (EPO):</strong> Consider if EPO level &lt;125 U/L (20% response rate)</li>
          <li><strong>Androgens (danazol):</strong> May improve anaemia in 30-40% (3-6 month trial)</li>
          <li><strong>Immunomodulatory drugs (thalidomide, lenalidomide):</strong> For anaemia ± thrombocytopenia (15-30% response, poorly tolerated)</li>
          <li><strong>Iron chelation:</strong> If transfusion-dependent and ferritin >1000 μg/L</li>
        </ul>

        <p><strong>D. Management of Splenomegaly:</strong></p>
        <ul>
          <li><strong>Ruxolitinib:</strong> First-line for symptomatic splenomegaly</li>
          <li><strong>Splenectomy:</strong>
            <ul>
              <li>Indications: Symptomatic massive splenomegaly refractory to ruxolitinib, severe hypersplenism, portal hypertension, recurrent splenic infarction</li>
              <li>High surgical morbidity/mortality (10-15%)</li>
              <li>Post-splenectomy thrombocytosis and thrombosis risk</li>
              <li>Accelerated hepatomegaly post-splenectomy (EMH shifts to liver)</li>
            </ul>
          </li>
          <li><strong>Splenic irradiation:</strong> Palliative option if surgery not feasible (temporary effect, risk of severe cytopenias)</li>
        </ul>

        <p><strong>E. Supportive Care:</strong></p>
        <ul>
          <li><strong>Allopurinol:</strong> For hyperuricaemia (prevent gout, tumor lysis syndrome)</li>
          <li><strong>Antihistamines:</strong> For pruritus</li>
          <li><strong>Nutritional support:</strong> Manage weight loss, early satiety</li>
          <li><strong>Analgesia:</strong> For bone pain</li>
          <li><strong>Thromboprophylaxis:</strong> If high thrombosis risk (high platelet count, JAK2+, previous thrombosis)</li>
          <li><strong>Vaccinations:</strong> If splenectomy or functional hyposplenism</li>
          <li><strong>Psychological support:</strong> Chronic progressive disease</li>
        </ul>

        <p><strong>Recommended Management for This Patient:</strong></p>
        <p>This patient has <strong>intermediate-2 risk disease</strong> (DIPSS 4 points) with symptomatic disease (massive splenomegaly, constitutional symptoms, anaemia).</p>

        <p><strong>Immediate Management:</strong></p>
        <ol>
          <li><strong>Start ruxolitinib</strong> (15-20mg BD) to reduce spleen size and improve constitutional symptoms</li>
          <li><strong>Transfusion support</strong> for symptomatic anaemia</li>
          <li><strong>Allopurinol</strong> for hyperuricaemia</li>
          <li><strong>Monitor blood counts closely</strong> (ruxolitinib can worsen anaemia/thrombocytopenia)</li>
        </ol>

        <p><strong>Longer-term Considerations:</strong></p>
        <ul>
          <li><strong>Assess for allogeneic HSCT eligibility:</strong>
            <ul>
              <li>Age 68 - borderline but may be candidate if good performance status</li>
              <li>HLA typing of patient and siblings</li>
              <li>Comorbidity assessment</li>
              <li>If eligible: Consider transplant referral (especially if good response to ruxolitinib)</li>
            </ul>
          </li>
          <li><strong>Clinical trial enrollment</strong> (newer JAK inhibitors, combination therapies)</li>
          <li><strong>Monitor for AML transformation</strong> (regular FBC, peripheral blood film for blasts)</li>
        </ul>
      </div>
    </div>

    <h2>Key Learning Points</h2>
    <div class="key-points">
      <ul>
        <li><strong>Myelofibrosis</strong> is a Philadelphia-negative myeloproliferative neoplasm characterized by bone marrow fibrosis, extramedullary haematopoiesis, and constitutional symptoms</li>
        <li><strong>Massive splenomegaly</strong> (often >10cm below costal margin) is the hallmark feature, caused by extramedullary haematopoiesis</li>
        <li><strong>Tear-drop cells (dacrocytes)</strong> and <strong>leukoerythroblastic blood picture</strong> on blood film are pathognomonic features</li>
        <li><strong>JAK2 V617F mutation</strong> present in 50-60% of cases (CALR 25%, MPL 8%) - driver mutations activate JAK-STAT pathway</li>
        <li>Bone marrow trephine biopsy shows <strong>reticulin/collagen fibrosis</strong> and <strong>"dry tap"</strong> on aspiration due to dense fibrosis</li>
        <li>Can arise de novo (primary myelofibrosis) or evolve from polycythaemia vera or essential thrombocythaemia (post-PV/ET myelofibrosis - "spent phase")</li>
        <li><strong>DIPSS score</strong> (age >65, constitutional symptoms, Hb &lt;100, WCC >25, blasts ≥1%) stratifies prognosis: Low, Int-1, Int-2, High risk</li>
        <li><strong>Constitutional symptoms</strong> (fatigue, weight loss, night sweats, bone pain) are common and reflect hypercatabolic state from high cell turnover and cytokine release</li>
        <li><strong>Ruxolitinib (JAK1/2 inhibitor)</strong> is first-line treatment for symptomatic disease - reduces spleen size and improves symptoms but is NOT curative</li>
        <li><strong>Allogeneic HSCT is the ONLY curative treatment</strong> - reserved for intermediate-2/high-risk patients age &lt;70 with adequate performance status</li>
        <li>Complications include transformation to AML (10-20%), thrombosis, bleeding, portal hypertension, splenic infarction, and cord compression from EMH</li>
        <li>Prognosis varies widely: Low-risk may survive >15 years, high-risk &lt;2 years. Median overall survival ~6 years</li>
      </ul>
    </div>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/dark-mode.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/user-analytics.js"></script>
  <script src="../js/analytics-integration.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        }
      }
    }// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          }
        }, 100);
      }
    });
    }
  </script>

</body>
</html>
